Journal article

Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds

Peter Wong, Nathan Lawrentschuk, Damien M Bolton

CURRENT OPINION IN UROLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2009

Abstract

PURPOSE OF REVIEW: Phosphodiesterase 5 (PDE-5) inhibitors are established as first-line therapy in erectile dysfunction. There is emerging evidence that they may have a role in treating patients with lower urinary tract symptoms (LUTS) from benign prostatic hypertrophy. RECENT FINDINGS: All three commonly used PDE-5 inhibitors (sildenafil, vardenafil and tadalafil) appear to improve LUTS as measured by the International Prostate Symptom Score. However, to date, no change in urinary flow rates have been demonstrated. SUMMARY: Erectile dysfunction and LUTS frequently coexist in men of advancing age. There appears to be an emerging role for PDE-5 inhibitors as a treatment for both conditions. F..

View full abstract